rfk glp 1 Experts Say GLP-1 Drugs Have Potential Use Beyond Weight Loss RFK Jr. is not a

An important decrease was observed in the gastrointestinal system symptoms of the intervention and control groups

The SURMOUNT-5 trial, published in 2025 in the New England Journal of Medicine, directly compared tirzepatide with semaglutide

Mice were housed in a temperature-controlled room with a 12-h light/dark cycle, 40%60% humidity, and ad libitum access to water and food

First, there were no significant differences within minimal/mild or moderate groups when given MSG as compared to placebo, but there was a significant LS mean difference for the severe group, where higher anxiety symptoms were reported during MSG challenge as compared to placebo ( t = 2.60, p = 0.03)

These inhibitors represent a more conservative pharmaceutical approach compared to GLP-1 receptor agonists like semaglutide (Ozempic)